Last January, a blip on the viral radar went unnoticed by much of the world. By the time the public became aware of an emerging pestilence—soon to be known as COVID-19—infectious disease researchers at Tarrytown-based Regeneron Pharmaceuticals, Inc., were already on the hunt for new drugs that could combat the disease.
Dr. Alina Baum, Associate Director for Infectious Diseases at Regeneron, is a trained virologist who has been with the company for almost six years and leads a 12-person research team. She recalled the urgency felt in the wake of the rising numbers COVID cases, hospitalizations, and deaths. “In New York in April, it was terrifying,” she said. “Some of the people in my group were working 80-hour weeks trying to get a drug to the clinic.”
In February, the company started laboratory research; by June, their first human clinical trials testing treatment against COVID-19 were underway.
Author(s): Sherrie Dulworth
Publication Date: 25 August 2021
Publication Site: The Examiner News